» Articles » PMID: 26514749

Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance Vs Treatment Failure

Overview
Journal Can J Cardiol
Publisher Elsevier
Date 2015 Oct 31
PMID 26514749
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Resistant or difficult to treat hypertension is defined as high blood pressure that remains uncontrolled with 3 or more different antihypertensive medications, including a diuretic. Recent definitions also include controlled blood pressure with use of 4 or more medications as also being resistant to treatment. Recently, refractory hypertension, an extreme phenotype of antihypertensive treatment failure has been defined as hypertension uncontrolled with use of 5 or more antihypertensive agents, including a long-acting thiazide diuretic and a mineralocorticoid receptor antagonist. Patients with resistant vs refractory hypertension share similar characteristics and comorbidities, including obesity, African American race, female sex, diabetes, coronary heart disease, chronic kidney disease, and obstructive sleep apnea. Patients with refractory vs resistant hypertension tend to be younger and are more likely to have been diagnosed with congestive heart failure. Refractory hypertension might also differ from resistant hypertension in terms of underlying cause. Preliminary evidence suggests that refractory hypertension is more likely to be neurogenic in etiology (ie, heightened sympathetic tone), vs a volume-dependent hypertension that is more characteristic of resistant hypertension in general.

Citing Articles

Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement.

Schlaich M, Tsioufis K, Taddei S, Ferri C, Cooper M, Sindone A J Hypertens. 2024; 42(12):2025-2040.

PMID: 38747424 PMC: 11556879. DOI: 10.1097/HJH.0000000000003769.


Resistant Hypertension: Disease Burden and Emerging Treatment Options.

Flack J, Buhnerkempe M, Moore K Curr Hypertens Rep. 2024; 26(5):183-199.

PMID: 38363454 PMC: 11533979. DOI: 10.1007/s11906-023-01282-0.


Chronic red laser treatment induces hypotensive effect in two-kidney one-clip model of renovascular hypertension in rat.

Dos Santos Carvalho Schiavon M, de Moraes L, de Moraes T, Buzinari T, Neto J, Rodrigues G Lasers Med Sci. 2023; 38(1):252.

PMID: 37919476 DOI: 10.1007/s10103-023-03918-8.


Apparently Resistant Hypertension in Polish Hemodialyzed Population: Prevalence and Risk Factors.

Symonides B, Lewandowski J, Marcinkowski W, Zawierucha J, Prystacki T, Malyszko J J Clin Med. 2023; 12(16).

PMID: 37629449 PMC: 10455257. DOI: 10.3390/jcm12165407.


Identification of a Gut Commensal That Compromises the Blood Pressure-Lowering Effect of Ester Angiotensin-Converting Enzyme Inhibitors.

Yang T, Mei X, Tackie-Yarboi E, Akere M, Kyoung J, Mell B Hypertension. 2022; 79(8):1591-1601.

PMID: 35538603 PMC: 9278702. DOI: 10.1161/HYPERTENSIONAHA.121.18711.


References
1.
Calhoun D, Jones D, Textor S, Goff D, Murphy T, Toto R . Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51(6):1403-19. DOI: 10.1161/HYPERTENSIONAHA.108.189141. View

2.
Calhoun D, Nishizaka M, Zaman M, Thakkar R, Weissmann P . Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002; 40(6):892-6. DOI: 10.1161/01.hyp.0000040261.30455.b6. View

3.
Cushman W, Ford C, Cutler J, Margolis K, Davis B, Grimm R . Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002; 4(6):393-404. DOI: 10.1111/j.1524-6175.2002.02045.x. View

4.
Konishi Nishizaka M, Zaman M, Calhoun D . Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003; 16(11 Pt 1):925-30. DOI: 10.1016/s0895-7061(03)01032-x. View

5.
Gaddam K, Nishizaka M, Pratt-Ubunama M, Pimenta E, Aban I, Oparil S . Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008; 168(11):1159-64. PMC: 2748247. DOI: 10.1001/archinte.168.11.1159. View